Nuzyra is an antibiotic used to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) [1]. It is a tetrasubstituted tetracycline class drug [1].
What infections can Nuzyra treat?
Nuzyra is FDA-approved for two main types of bacterial infections:
* Community-Acquired Bacterial Pneumonia (CABP): This refers to pneumonia acquired outside of a hospital setting [1].
* Acute Bacterial Skin and Skin Structure Infections (ABSSSI): This category includes infections affecting the skin and the tissues beneath it [1].
How does Nuzyra work?
Nuzyra is a protein synthesis inhibitor [1]. It works by binding to the bacterial 30S ribosomal subunit, which is essential for bacterial growth and replication [1]. By inhibiting this process, Nuzyra effectively stops bacteria from multiplying [1].
When does Nuzyra's patent protection expire?
The patent landscape for Nuzyra is complex and involves multiple patents. According to DrugPatentWatch.com, the earliest key patent for Nuzyra is expected to expire in 2034 [2]. However, other patents related to the drug and its formulations could extend protection beyond this date [2].
What are the risks and side effects associated with Nuzyra?
Nuzyra carries a boxed warning regarding the risk of death, including from serious liver injury, in patients with the indication of CABP and in patients with underlying severe comorbidities who are critically ill and receiving Nuzyra for ABSSSI [1]. Other serious side effects can include severe diarrhea due to Clostridioides difficile infection, and potential for fetal harm since Nuzyra can cause P-integumentary permanent tooth discoloration and enamel hypoplasia in fetuses and in infants up to 8 years old [1].
Common side effects reported in clinical trials include nausea, vomiting, diarrhea, and infusion-related reactions [1].
Are there alternative treatments for the infections Nuzyra treats?
Yes, there are several alternative antibiotic classes and specific drugs available for treating CABP and ABSSSI, depending on the specific pathogen, severity of infection, and patient factors. These can include beta-lactams, macrolides, fluoroquinolones, and other tetracycline derivatives [3]. The choice of treatment is guided by local resistance patterns and patient-specific characteristics.
What is the typical dosage and administration of Nuzyra?
Nuzyra is administered intravenously (IV) [1]. For CABP, the recommended dosage is 1,000 mg every 24 hours for 7 days [1]. For ABSSSI, the recommended dosage is 1,000 mg on day 1, followed by 500 mg every 24 hours for 4 to 14 days [1].
Who manufactures Nuzyra?
Nuzyra is manufactured by Hikma Pharmaceuticals [1].
What is the cost of Nuzyra?
Information on the exact cost of Nuzyra can vary based on insurance coverage, pharmacy, and location. However, as a branded prescription medication, it is generally considered expensive. Pricing details are typically available through pharmaceutical pricing databases or by contacting the manufacturer directly.
What is the clinical data supporting Nuzyra's use?
Nuzyra's efficacy for CABP was demonstrated in a Phase 3 OPTIC study, where it met its primary endpoint of non-inferiority to levofloxacin [1]. For ABSSSI, its effectiveness was shown in a Phase 3 SECURE study, meeting its primary endpoint of non-inferiority to vancomycin [1].
How do Nuzyra's patents compare to other similar drugs?
The patent protection for Nuzyra, as tracked by DrugPatentWatch.com, places its patent expiry around 2034 [2]. This timeframe is typical for many newly approved branded pharmaceuticals, providing a period of market exclusivity before generic or biosimilar competition can emerge [2]. The specific duration of exclusivity can be influenced by various factors, including regulatory exclusivities and additional patents covering manufacturing processes or formulations.
---
Sources:
[1] https://www.nuzyra.com/
[2] https://drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608901/